- Home
- |
- Contact
- |
- Pharmacovigilance
- |
Welcome to
Chiesi group
Guaranteeing the highest ethical standards is a daily priority for Chiesi in every aspect of its business. This means doing business on the basis of the principles of legality, fairness, integrity, responsibility and transparency.
In this regard, also in compliance with the laws and regulations in force, we have adopted a specific Code of Conduct and since 2005 all our subsidiaries have been progressively involved in the implementation of the Group Code of Conduct.
Furthermore, Chiesi Farmaceutici S.p.A. has implemented a specific Organisational, Management and Control Model (known as Model 231) in Italy.
In order to uphold the high legal and moral standards of the Group, Chiesi also adopted an Anti-Corruption Policy in 2015. The purpose of this policy is to provide anyone acting on behalf of or in the interests of Chiesi with a series of general principles on how to recognise and deal with situations involving corruption and how to comply with related regulations, which are in line with the provisions set out in Chiesi’s Code of Ethics and Conduct.
As a pharmaceutical company, the Chiesi Group works closely with the scientific community by constantly exchanging knowledge, achieving significant progress in the scientific world for the benefit and protection of patient health, once again in accordance with the codes and provisions regulating our sector.
Based on the rules set out in the Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organizations, relating to transparency regarding the transfer of value between pharmaceutical companies, Healthcare Professionals and Healthcare Organisations, which are indicated by the EFPIA (European Federation of Pharmaceutical Industries) and also acknowledged in the Farmindustria Code of Conduct, our company has committed itself to making data relating to these transfers of value public at European level each year beginning in 2015 (first publication June 30th 2016).
From 30 June 2022, here below on the Chiesi Farmaceutici S.p.A. website it is provided a detailed report of any financial transactions made by Chiesi Farmaceutici SpA in Italy during 2021 towards Healthcare Professionals and Healthcare Organizations.
With regard to Healthcare Professionals, these cover expenses for taking part in conferences and congresses and expenditure for consultancy work and professional services regulated by specific contracts.
With regard to Healthcare Organizations, these relate to donations and contributions either in the form of money or in kind made to sponsor scientific events providing specialized training and pay for consultancy work and professional services covered by a written agreement between Chiesi and other institutions, organisations or associations.
For information on the regulations introduced by the “Code on Disclosure of Transfers of Value from pharmaceutical firms, healthcare professionals and organizations”, please consult the following website: www.farmindustria.it (from the Home Page go to the Deontological Code section) or contact the Chiesi Transparency Contact Point at the following email address: dpoit@chiesi.com.
For requests made by the media, please contact Group.Communication@chiesi.com
REPORT
This is the content of Tab 2.
